

Enesi Pharma is an innovative pharmaceutical company developing needle-free solid dose products with the potential to transform performance and delivery of vaccines and make a material impact on global healthcare



Enesi Pharma Limited

120 A&B Olympic Avenue, Milton Park
Abingdon, Oxfordshire, OX14 4SA United Kingdom
Tel: +44 (0) 1235 577 120 / www.enesipharma.com
enquiries@enesipharma.com / [twitter: @enesi_pharma](https://twitter.com/enesi_pharma)



Immunity for Life



Enesi
Pharma

Immunity for Life

Enesi Pharma is an innovative pharmaceutical company developing needle-free solid dose vaccine products with the potential to transform performance and delivery of vaccines and make a material impact on global healthcare.

ImplaVax®


ImplaVax® is an innovative needle-free solid dose vaccine platform comprising three main components:

- A single precision-engineered solid dose Universal Vaccine Implant (UVI) containing the monovalent or multivalent vaccine or vector construct together with its associated excipient matrix that confers its mechanical strength and stability
- A separate, disposable unit dose cassette pre-loaded with a single UVI
- A handheld reusable spring-powered actuator

ImplaVax® enabled products have transformational potential for patients, health care professionals and payers alike including:

- Enhanced immune response for vaccines demonstrated compared to standard injection
- Needle-free delivery; no need to 'mix and shoot'
- Rapid administration, easy and intuitive to use for one-off and repeat-use regimens
- 100% unit dosing assured each time
- Eliminates risk of cross contamination and disease transmission between individuals from shared needles
- Strong subject group preference for Implavax® over traditional needle and syringe
- Reducing / eliminating need for cold-chain requirements
- Potentially least cost per delivered dose


Solid dose vaccine implant rabbit immunogenicity study



The Enesi solid dose implant demonstrates superior immune response to the active control.

Dosing at days 0 and 28.

Enesi F23-10-SC solid dose vaccine implant long term stability



Enesi F23-10-SC solid dose vaccine implant retains high potency over an extended time range of up to 15 months at ICH conditions up to 40°C and 75% RH as determined by a range of assays.

